News

Q&A with Le Thanh-Thao on trial data showing 25 mcg of JJA VIT matched 50 mcg efficacy, with safety and biomarker insights.

Phase 2 RAPIDe-1 trial shows an oral bradykinin B2 antagonist improves symptom relief and reduces rescue therapy use in hereditary angioedema attacks.

In this April episode, the discussion highlights how intentional choices and practice ownership can help physicians align professional with personal success.

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.

Brelovitug achieved the FDA-specified primary endpoint for HDV RNA reduction and normalization of ALT in a phase 2b trial.

Silverstein addresses a secondary analysis of the GRACE trial, highlighting relacorilant’s efficacy in reducing cortisol in patients taking GLP-1 RAs.

Low-dose radiation therapy is gaining attention in the US for osteoarthritis and inflammatory pain, with clinicians citing anti-inflammatory effects.

Inusa discusses how clinicians can close gaps in sickle cell disease care and global disparities.

Joshi explains the narrow window of optimal iodine levels, highlighting the risk posed by supplements and iodized salt in tipping the scales toward health risks.

Campbell answers questions about the current research and clinical landscape of APOL1-mediated kidney disease.

This Q&A interview highlights emerging therapies for atopic dermatitis, featuring Christopher G. Bunick, MD, PhD of Yale Medicine.

Brelovitug met the primary endpoint for virologic response and ALT normalization in the phase 2b portion of the AZURE-1 trial.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

Study investigator Inusa explains the gap in sickle cell disease findings from SWAP, a multinational survey.

Isaacs covers the range of AID devices currently available and approved for T2D, providing suggestions for implementation and continuous glycated hemoglobin monitoring.

In this Q&A interview, Bhatia discusses the FDA's recent acceptance of BLA for imsidolimab for generalized pustular psoriasis (GPP).

Study showed the PETRUSHKA decision-support tool reduced antidepressant discontinuation, supporting personalized treatment approaches.

The FDA has approved budesonide/glycopyrrolate/formoterol fumarate as the first single-inhaler triple therapy for asthma.

AbbVie submitted an sNDA to the FDA seeking approval of upadacitinib for severe alopecia areata in adults and adolescents.

Lu explains findings that link PCBP1 to the pathogenesis of AARS2-related cardiomyopathy.

The FDA granted Fast Track Designation to coramitug, an investigational anti-TTR antibody designed to clear existing amyloid deposits in ATTR cardiomyopathy.

The FDA has accepted bepirovirsen's NDA for Priority Review and granted Breakthrough Therapy designation, with a PDUFA date of October 26, 2026.

The phase 3 trials enrolled frequent exacerbators regardless of eosinophil count or smoking status.

Phase 3 HAELO data show an 87% reduction in hereditary angioedema attack rates with a one-time CRISPR therapy. Banerji discusses efficacy, safety, and durability.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

These Week 16, phase 2a findings from the EVERLAST-A study assessing ORKA-001 highlight the treatment's potential in those with plaque psoriasis.

Viral Shah, MD, joins the show to break down his AACE 2026 presentation on the benefits of using GLP-1 RAs in patients with T1D.

Kass explains recent findings from a study that suggest myocardial dysfunction in HFpEF may be reversible with weight loss.